 |
Italian Scientists and Scholars of North America Foundation
|
|
Home > USA > Meet Italy at Bio 2007
BIO3 RESEARCH S.r.l.
Via della Moscova, 6/8 - 20121 Milan,ITALY
Telephone: 0039 02 62694888
Fax: 0039 02 65589116
Web site: www.bio3research.com
E-mail: f.pilato@bio3research.com
Contact: Francesco Paolo Pilato (President & CEO); Federico Gardini (Business Development)
At a Glance
Status: SME
Date of foundation: 2001
Employees: 6.
Main Activity
Bio3 Research s.r.l. is an Italian private company based in Milan, with a representative office at the Bioindustry Park Canavese (Turin).
Bio3 Research develops IP generated in the Academy mainly in the field of HMGB1 related Cardiovascular disorders and use of HMGB1 and its fragments in Connective Tissue Regeneration.
Other Bio3 Research field of interest are skin and renal diseases. Bio3 works with research institutions, early-stage companies and individual scientists to identify commercially promising IPs and assists them in patenting their Innovations and bringing such IPs to the marketplace.
Bio3, on case by case basis, undertakes preclinical studies on some of its IPs to add value to innovative projects.
Using extensive industry experience and contacts, Bio3 develops and implements marketing and business strategies, identifies and negotiates with downstream "development partners" (licensees or buyers).
Bio3's assistance often takes the form of a license agreement for the intellectual property, for the purpose of granting sub-licenses to appropriate development partners.
Bio3 may also provide financial and other support to the research institutions, start-ups and scientists that it works with, including management and funding of patent strategies.
Company Strengths
LICENSES/TRADE MARKS/QUALITY CERTIFICATIONS/PATENTS: Preclinical development and patents
R&D CAPACITY: Preclinical activities via external laboratories
EXPERTISE: marketing, licensing, regulatory activities.
Customer References
- Bio3 Research has granted to the Latin American Daxley Group a license for Biocysan™ in Latin America and Mexico for its oral use in dialyzed patients to prevent severe anaemia.
- Bio3 Research has entered into a Research Agreements with Cephalon, Inc. (PA/USA) to evaluate the compound CT301/R (K252a) for its potential use in the prevention and treatment of restenosis
Sector
BIOTECHNOLOGY
MEDICAL BIOTECHNOLOGY
-biopharmaceutical
Type of Cooperation
GENERAL CO-OPERATION
-DEVELOPMENT OF NEW PRODUCTS
-NEW PROJECTS DEVELOPMENT
-TECHNOLOGY TRANSFER OR PRODUCTION LICENSE
|
|
